GLP-1 agonists studied for skin disorders and reduced breast cancer incidence

Recent reviews highlight that GLP‑1 receptor agonists, originally developed for type‑2 diabetes and weight management, may influence chronic inflammatory skin diseases. Pre‑clinical work, case reports and small cohort studies suggest potential benefits in psoriasis, atopic dermatitis, hidradenitis suppurativa and chronic wounds, likely through modulation of immune cells and reduction of cytokines such as TNF‑α, IL‑6 and IL‑17. Researchers note that the evidence is still early and further clinical trials are required.

A retrospective analysis of more than 110,000 overweight women aged 45‑80 found that users of GLP‑1 medications had roughly a 30‑35% lower incidence of breast cancer compared with non‑users. The study, presented at the 2026 ASCO meeting, was observational and did not control for drug type, treatment duration or tumor characteristics. Investigators are planning a multicenter prospective trial to assess whether GLP‑1 drugs could serve as a preventive strategy for high‑risk women.